$VRDN

2 theses

bullish 50%neutral 0%bearish 50%

Avg return (1d)

-1.4%

Win rate (1d)

50% (2 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 8, 4:31 PM ET

$VRDNSEC Form 4bearish

Tousignant Jennifer · Chief Legal Officer at Viridian Therapeutics, Inc.\DE · 20d agono track record yet

Sold 14,212 @ $24.50 avg · $348,194 · 2026-08-19

Form 4: Tousignant Jennifer sold VRDN

Tousignant Jennifer (Chief Legal Officer at Viridian Therapeutics, Inc.\DE) reported an open-market sale of 14,212 shares of VRDN at an average $24.50, roughly $348,194, in a Form 4 filed 2026-08-20.

At post $24.50Now $23.17-5.4% since postedas of Sep 8, 4:31 PM ET

1d-0.9%

3d-0.9%

1w-2.5%

1m—

3m—

6m—

1y—

View filing on SEC.gov →

$VRDNr/wallstreetbetsDDbullish

u/Buy-NVDA · 121d agono track record yet

Ez money VRDN

Viridian Therapeutics released Phase 3 data for TED showing strong efficacy (p < 0.0001) with a potentially best-in-class safety profile versus Amgen's Tepezza. With $1.1B in cash, institutional backing at $17.00, and a June 30 PDUFA decision as a near-term catalyst, the stock—currently trading below the offering price—has upside to analyst targets of $34+.

At post $17.20Now $23.17+34.7% since postedas of Sep 8, 4:31 PM ET

1d-2.0%

3d+1.3%

1w-6.4%

1m-8.3%

3m+37.2%

6m—

1y—

original post →

End of results.